# Innate Pharma SA: Form 20-F for the period ended Dec 31, 2021

- Company: [Innate Pharma SA](/companies/ipha.md) (CIK 1598599)
- Form: 20-F
- Filed: 2022-04-04
- Accepted by EDGAR: Apr 4, 2022, 06:19 ET
- Period: 2021-12-31
- Accession: 0001628280-22-008197
- Inline XBRL: yes
- Main document: https://www.sec.gov/Archives/edgar/data/1598599/000162828022008197/inpha-20211231.htm
- All documents and exhibits: https://www.sec.gov/Archives/edgar/data/1598599/000162828022008197/

## Figures reported in this filing

Standardized XBRL line items for the period ended 2021-12-31.

| Line item | Period | Value | XBRL concept |
| --- | --- | ---: | --- |
| Revenue | 12 months, 2021-01-01 to 2021-12-31 | EUR 24.7m | ifrs-full:Revenue |
| Operating income | 12 months, 2021-01-01 to 2021-12-31 | −EUR 47.8m | ifrs-full:ProfitLossFromOperatingActivities |
| Income tax | 12 months, 2021-01-01 to 2021-12-31 | EUR 0 | ifrs-full:IncomeTaxExpenseContinuingOperations |
| Net income | 12 months, 2021-01-01 to 2021-12-31 | −EUR 52.8m | ifrs-full:ProfitLoss |
| Diluted EPS | 12 months, 2021-01-01 to 2021-12-31 | −EUR 0.66 | ifrs-full:DilutedEarningsLossPerShare |
| Basic EPS | 12 months, 2021-01-01 to 2021-12-31 | −EUR 0.66 | ifrs-full:BasicEarningsLossPerShare |
| Operating cash flow | 12 months, 2021-01-01 to 2021-12-31 | −EUR 58.5m | ifrs-full:CashFlowsFromUsedInOperatingActivities |
| Capital expenditure | 12 months, 2021-01-01 to 2021-12-31 | EUR 929.0k | ifrs-full:PurchaseOfPropertyPlantAndEquipmentClassifiedAsInvestingActivities |
| Cash and equivalents | at 2021-12-31 | EUR 103.8m | ifrs-full:CashAndCashEquivalents |
| Current assets | at 2021-12-31 | EUR 138.3m | ifrs-full:CurrentAssets |
| Total assets | at 2021-12-31 | EUR 267.5m | ifrs-full:Assets |
| Current liabilities | at 2021-12-31 | EUR 79.9m | ifrs-full:CurrentLiabilities |
| Shareholders' equity | at 2021-12-31 | EUR 107.4m | ifrs-full:Equity |
| Shares outstanding | at 2021-12-31 | 79,542,627 shares | dei:EntityCommonStockSharesOutstanding |

## Sections

Sections are extracted only from 10-K and 10-Q reports. Read this filing’s documents on sec.gov. https://www.sec.gov/Archives/edgar/data/1598599/000162828022008197/inpha-20211231.htm

Filed Apr 4, 2022.
Source: SEC EDGAR, the filing index for accession 0001628280-22-008197. Last ingested by Listed: Oct 27, 2026, 07:14 ET. No prices; not investment advice.